{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:54:52Z","timestamp":1760144092740,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue de Pneumologie Clinique"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.pneumo.2017.08.012","type":"journal-article","created":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T04:45:10Z","timestamp":1511325910000},"page":"326-330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effets secondaires inhabituels des immunoth\u00e9rapies dans le cancer bronchique non \u00e0 petites cellules\u00a0: \u00e0 propos de deux cas"],"prefix":"10.1016","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6660-5374","authenticated-orcid":false,"given":"G.","family":"de Chabot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2137-113X","authenticated-orcid":false,"given":"G.","family":"Justeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Pinqui\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Nadaj-Pakleza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Hopp\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3941-3860","authenticated-orcid":false,"given":"J.","family":"Hureaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Urban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pneumo.2017.08.012_bib0085","first-page":"11","article-title":"Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports","author":"Abdel-Wahab","year":"2016","journal-title":"Plos One"},{"key":"10.1016\/j.pneumo.2017.08.012_bib0090","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.pneumo.2017.08.012_bib0095","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/WCO.0000000000000391","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"29","author":"Hottinger","year":"2016","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.pneumo.2017.08.012_bib0100","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.pneumo.2017.08.012_bib0105","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1634\/theoncologist.2016-0055","article-title":"Management of adverse events following treatment with anti-programmed death-1 agents","volume":"21","author":"Weber","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.pneumo.2017.08.012_bib0110","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.pneumo.2017.08.012_bib0115","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fimmu.2014.00206","article-title":"Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1","volume":"5","author":"Kong","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.pneumo.2017.08.012_bib0120","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.lungcan.2016.10.008","article-title":"Corneal graft rejection in a patient treated with nivolumab for primary lung cancer","volume":"102","author":"Le Fournis","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.pneumo.2017.08.012_bib0125","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.25141","article-title":"Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab","volume":"54","author":"Lau","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.pneumo.2017.08.012_bib0130","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.nmd.2017.01.002","article-title":"Myasthenia triggered by immune checkpoint inhibitors: new case and literature review","volume":"27","author":"Gonzalez","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.pneumo.2017.08.012_bib0135","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/CMR.0000000000000310","article-title":"Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients","volume":"27","author":"Nguyen","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.pneumo.2017.08.012_bib0140","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/cas.12961","article-title":"Myasthenic crisis and polymyositis induced by one dose of nivolumab","volume":"107","author":"Kimura","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/j.pneumo.2017.08.012_bib0145","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/art.1780130607","article-title":"Synovial fluid findings in systemic lupus erythematosus (SLE)","volume":"13","author":"Zvaifler","year":"1970","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pneumo.2017.08.012_bib0150","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/0961203308093923","article-title":"Association of programmed cell death 1 polymorphisms and systemic lupus erythematosus: a meta-analysis","volume":"18","author":"Lee","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.pneumo.2017.08.012_bib0155","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.pneumo.2017.08.012_bib0080","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.9012","article-title":"Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy","volume":"35","author":"Santini","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Revue de Pneumologie Clinique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761841717301165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761841717301165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:17:44Z","timestamp":1760105864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761841717301165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0761841717301165"],"URL":"https:\/\/doi.org\/10.1016\/j.pneumo.2017.08.012","relation":{},"ISSN":["0761-8417"],"issn-type":[{"type":"print","value":"0761-8417"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effets secondaires inhabituels des immunoth\u00e9rapies dans le cancer bronchique non \u00e0 petites cellules\u00a0: \u00e0 propos de deux cas","name":"articletitle","label":"Article Title"},{"value":"Revue de Pneumologie Clinique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pneumo.2017.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}